Home » Roche Gains Rights to Eye Drug From Lineage Cell Therapeutics
Roche Gains Rights to Eye Drug From Lineage Cell Therapeutics
Roche’s Genentech subsidiary has struck a deal with Lineage Cell Therapeutics to license and develop the latter’s investigational eye drug — a retinal pigment epithelium (RPE) therapy being prepped for a form of advanced dry age-related macular degeneration.
Under the deal, Roche will pay Lineage $50 million upfront and potentially a further $620 million in milestones-based payments as well as royalties on sales.
Lineage is currently assessing the drug in an early-phase study, but Roche will handle all future clinical development for the product.
Upcoming Events
-
07May
-
14May
-
30May